225 related articles for article (PubMed ID: 32739923)
1. TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update.
Vulliemoz M; Brand S; Juillerat P; Mottet C; Ben-Horin S; Michetti P;
Digestion; 2020; 101 Suppl 1():16-26. PubMed ID: 32739923
[TBL] [Abstract][Full Text] [Related]
2. TNF-alpha blockers in inflammatory bowel diseases: practical consensus recommendations and a user's guide.
Pache I; Rogler G; Felley C
Swiss Med Wkly; 2009 May; 139(19-20):278-87. PubMed ID: 19452290
[TBL] [Abstract][Full Text] [Related]
3. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
4. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
[TBL] [Abstract][Full Text] [Related]
5. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
Aardoom MA; Veereman G; de Ridder L
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
[TBL] [Abstract][Full Text] [Related]
6. A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease.
Mosli MH; Al-Harbi O; Feagan BG; Almadi MA
Saudi J Gastroenterol; 2015; 21(4):185-97. PubMed ID: 26228361
[TBL] [Abstract][Full Text] [Related]
7. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease.
Cohen BL; Sachar DB
BMJ; 2017 Jun; 357():j2505. PubMed ID: 28630047
[TBL] [Abstract][Full Text] [Related]
8. Timing of proper introduction, optimization and maintenance of anti-TNF therapy in IBD: Results from a Delphi consensus.
Ardizzone S; Armuzzi A; Caprioli F; Castiglione F; Danese S; Daperno M; Fantini MC; Fries W; Principi MB; Savarino E; Gionchetti P
Dig Liver Dis; 2024 Jan; 56(1):98-105. PubMed ID: 37741750
[TBL] [Abstract][Full Text] [Related]
9. Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review.
Gisbert JP; Chaparro M
Gastroenterol Hepatol; 2018; 41(6):389-405. PubMed ID: 29753532
[TBL] [Abstract][Full Text] [Related]
10. Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease.
Pouillon L; Bossuyt P; Peyrin-Biroulet L
Expert Opin Biol Ther; 2016 Oct; 16(10):1277-90. PubMed ID: 27329436
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus.
Greuter T; Maillard MH; Juillerat P; Michetti P; Seibold F; Mottet C; Zahnd N; Sauter B; Schoepfer AM; Rogler G; Vavricka SR;
Digestion; 2020; 101(6):683-691. PubMed ID: 31461706
[TBL] [Abstract][Full Text] [Related]
12. An update on biosimilar drugs for inflammatory bowel disease.
Schreiber S
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
[TBL] [Abstract][Full Text] [Related]
13. [Biologics in current therapy for inflammatory bowel disease].
Hisamatsu T; Hibi T
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Jun; 32(3):168-79. PubMed ID: 19564713
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology and metabolism of infliximab biosimilars - A new treatment option in inflammatory bowel diseases.
Włodarczyk M; Fichna J; Sobolewska-Włodarczyk A
Pharmacol Rep; 2016 Aug; 68(4):797-801. PubMed ID: 27162107
[TBL] [Abstract][Full Text] [Related]
15. Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
Porcari S; Viola A; Orlando A; Privitera AC; Ferracane C; Cappello M; Vitello A; Siringo S; Inserra G; Magnano A; Mocciaro F; Di Mitri R; Belluardo N; Fidanza O; Garufi S; Magrì G; Bertolami C; Carroccio A; Macaluso FS; Renna S; Ventimiglia M; Alibrandi A; Cottone M; Fries W;
Drugs Aging; 2020 May; 37(5):383-392. PubMed ID: 32016824
[TBL] [Abstract][Full Text] [Related]
16. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T
Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
[TBL] [Abstract][Full Text] [Related]
17. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
18. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.
Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A
Aliment Pharmacol Ther; 2017 Apr; 45(8):1043-1057. PubMed ID: 28239873
[TBL] [Abstract][Full Text] [Related]
19. [Anti-TNF biosimilars in chronic inflammatory bowel disease. What can rheumatologists learn from it?].
Schreiber S
Z Rheumatol; 2015 Oct; 74(8):689-94. PubMed ID: 26450434
[TBL] [Abstract][Full Text] [Related]
20. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.
Radin M; Sciascia S; Roccatello D; Cuadrado MJ
BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]